Uncategorized

Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. – January 2, 2019 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019.

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

α_vβ₈

Morphic is developing small molecule inhibitors of the integrin α_vβ₈ through a combination immuno-oncology approach for the treatment of solid tumors as well as potential additional indications. α_vβ₈ is known to activate selective isoforms of TGF-β and Morphic has demonstrated that α_vβ₈ inhibition can potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s α_vβ₈ inhibitors are in preclinical development.

Next Gen α₄β₇ Inhibitors

Morphic is developing a family of next generation α₄β₇ small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α₄β₇ inhibitors are currently in preclinical development.

Uncategorized

Contact Us

Integrin Partnership: Janssen

Undisclosed Targets

Undisclosed Target for Pulmonary Arterial Hypertension

αvβ8

Next Gen α4β7 Inhibitors

α_vβ₈

Next Gen α₄β₇ Inhibitors